#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Epstein-Barr virus infection Non-Hodgkin's lymphoma refractory Systemic candida Dementia Alzheimer's type Keratosis follicular Interstitial lung disease Alveolar rhabdomyosarcoma Pleomorphic liposarcoma Follicular lymphoma Hypertriglyceridaemia Toxic epidermal necrolysis Thyroid cancer metastatic Waldenstrom's macroglobulinaemia refractory Pleural mesothelioma malignant Polyneuropathy More trials…

    Learn about Rare Diseases

    Haemophagocytic lymphohistiocytosis – Diagnostics Wolfram syndrome – Basic Information Pulmonary fibrosis – Trials in Disease Advanced systemic mastocytosis Haemolytic uraemic syndrome – Diagnostics Cerebral arteriovenous malformation haemorrhagic – Diagnostics Pemphigus – Diagnostics Cholangitis sclerosing – Life with Disease Fragile X syndrome – Life with Disease Mantle cell lymphoma stage IV – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mcla-129 Resatorvid Vibosameran Ammonium Chloride Bp Relugolix Thalidomide Cetrelimab SURVODUTIDE Sodium Phosphate Lithium Sulphate, Anhydrous Adrenaline Acid Tartrate Bp Insulin Icodec Trimetazidine Dihydrochloride Pramipexole Skin Autograft Panobinostat Aminocaproic Acid Nvl-655 Tomligisiran Elvn-002-1 More therapies…

    Learn about Your Condition

    Hepatic adenoma Hot flush Aneurysm ruptured Metastasis Renal injury Hyperparathyroidism secondary Essential hypertension Small for dates baby Osteosarcoma recurrent Wiskott-Aldrich syndrome Trisomy 21 Stomatitis Pancreatic carcinoma Infertility Polycythaemia vera More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant melanoma

  • Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Bladder cancer
    • Head and neck cancer
    Investigated Drugs:
    • Atezolizumab
    • Durvalumab
    • Ipilimumab
    Hungary

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Hepatocellular carcinoma
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • RP2
    • RP3
    France Germany Greece Poland Spain

  • A Study Comparing MB11 and Nivolumab in Adults With Previously Untreated Advanced or Metastatic Melanoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Nivolumab
    Greece Italy Poland Portugal Romania Slovakia +1

  • Study to Evaluate IOpener-Melanoma Test for Predicting Response to Immunotherapy in Stage III or IV Skin Melanoma Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Nivolumab
    • Pembrolizumab
    The Netherlands

  • Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

    Recruiting

    2 1 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Italy Poland Portugal +1

  • Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • Relatlimab
    • Dacarbazine Citrate
    France Germany Greece Italy Poland Spain
1 2 3 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!